Neurofibromatosis-related phaeochromocytoma: two cases with large tumours and elevated plasma methoxytyramine.
We present two cases of adrenal phaeochromocytoma in patients with a previous diagnosis of neurofibromatosis type 1 (NF1). One had an adrenergic phenotype. The other had a more noradrenergic phenotype. Both had large primary tumours, which increases the likelihood of malignancy. Both also had elevated plasma-free methoxytyramine, which has been linked with malignancy even in non-SDHB phaeochromocytomas.


CONCLUSIONS
Phaeochromocytoma can have varied clinical presentations.Methoxytyramine can be useful in the biochemical work-up of both SDHB-positive and SDHB-negative phaeochromocytoma.The utility of methoxytyramine as a marker of malignancy in NF1-related phaeochromocytoma is unclear, and cases with elevated titres warrant longer follow-up.
Endocrinology , Mater Hospital , South Brisbane, Queensland , Australia.
Stephanie
S
Teasdale
Endocrinology , Gold Coast University Hospital , Southport, Queensland , Australia.
Elham
E
Reda